*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Formulation and in vivo evaluation of osmotic drug delivery system of Repaglinide

Author: PARAS POPHALKAR, SARITA KAROLE
Abstract: The osmotic drug delivery system (ODDS) of Repaglinide was prepared using a semi-permeable membrane-coated tablet with an osmotic core. The core contained Repaglinide as the active pharmaceutical ingredient, along with osmotic agents to generate an osmotic gradient for controlled drug release. The drug-loaded core was coated with the semipermeable membrane to control the release rate. Furthermore, in vivo evaluation of the ODDS was performed using rabbit models. The rabbits were administered with the ODDS orally, and blood samples were collected at predetermined intervals to determine the plasma concentration of Repaglinide. The pharmacokinetic parameters such as Tmax, Cmax, and AUC were calculated to assess the drug release profile and bioavailability of the ODDS. The results demonstrated that the ODDS exhibited a sustained and controlled release of Repaglinide. The release profile was pH-dependent, with faster release at higher pH values. The in vivo evaluation revealed a prolonged and consistent release of Repaglinide, leading to enhanced bioavailability compared to the conventional immediate-release formulation. Overall, the developed ODDS of Repaglinide showed promising results in terms of controlled release. This system has the potential to enhance patient compliance and provide better therapeutic outcomes to treat diabetes mellitus. Further optimization and comprehensive studies are warranted to evaluate the extended efficacy and safety of the ODDS.
Keyword: Osmotic drug delivery system, Repaglinide drug, controlled release, in vivo evaluation, bioavailability, antidiabetic agent.
DOI: https://doi.org/10.31838/ijpr/2023.15.02.004
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free